Recent Media Coverage
- Health Business Blog-eCOA in action: Podcast interview with iCardiac CEO, Alex Zapesochny-Electronic clinical outcome assessment (eCOA) platforms collect data from patients, clinicians and caregivers to make clinical trials more efficient and accurate. Read more
- Outsourcing Pharma-iCardiac eCOA platform a ‘major step forward,’ says CEO: iCardiac’s new eCOA platform, QPoint, can measure clinical outcome assessments from patients at home or during site visits and will soon integrate with emerging wearables. Read more
Rochester Business Journal-Taking leadership to heart: Born in the former Soviet Union, Alex Zapesochny did not grow up wanting to be an entrepreneur. Today, he leads one of Rochester’s fastest-growing privately held firms, iCardiac Technologies Inc. Read more
- Rochester Chamber Top 100 announced; iCardiac ranks No. 4: Since 1988, each annual Top 100 has ranked the area’s private companies based on dollar and percentage revenue increases over the past three fiscal years. Read more
- OutSourcing Pharma-iCardiac collaborating with Japanese SMO to conduct cardiac safety studies: iCardiac Technologies and SNBL CPC Japan, a Japanese-based Site Management Organization (SMO), will collaborate on cardiac safety studies in the country. Read more
- PharmaVOICE-PharmaVOICE 100: Alex Zapesochny-Optimizing Clinical Trial Efficiency: A lawyer, a boxer, and a writer walk into a company to discuss innovative ways for cost-effective safety testing for drugs with an entrepreneur. Read more
- Democrat & Chronicle-Spotlight: iCardiac Technologies Runs Clinical Trials: A Brighton company, iCardiac Technologies, is doing work to get the most precise test data and results possible. That means getting more of the right drugs to the people who need them. Read more
- BioSpace-iCardiac Technologies Launches Global Late Phase Respiratory And Cardiac Safety Study Spanning 28 Countries: Rochester, NY – iCardiac Technologies, Inc., a market leader in the conduct of respiratory and cardiac safety studies, today announced it was awarded and is now enrolling patients in the largest late phase respiratory and cardiac safety study in the company’s history. Read more
- Applied Clinical Trials-An Alternative Path to TQT Studies: In December 2015, the ICH updated its E14 Guideline Q & A to define an alternative path for identifying the cardiac safety issue of QT prolongation in non-cardiac drugs. Read more
- DDN News-Heart Smart: iCardiac Technologies Inc. is taking part in an industry-wide validation program organized by the Cardiac Safety Research Consortium, the company announced recently. Read more
- Journal of Clinical Studies: John Sage, senior vice president of respiratory and ePRO services at iCardiac Technologies, discusses electronic Patient Reported Outcomes and their role in complex clinical trials. Read more: Going All-in on ePRO
- Health Business Blog-Is Generally Regarded as Safe (GRAS) safe enough? Unlike most people exposed to the “Frontline” investigation of supplements and vitamins, I really didn’t find it shocking that a lot of supplements are dangerous and that the bottles don’t contain what they say they do. I feel sorry for people who take these products and are not helped –and are even harmed– but frankly the customers should know better. Read more
- CenterWatch- ICH revises regulatory path in TQT clinical studies: Rochester, N.Y.-based iCardiac Technologies, a provider of cardiac safety assessments, has voiced support of the official release of a regulatory revision enacted by the International Council for Harmonization (ICH) that defines and enables an alternative path to the conduct of a Thorough QT (TQT) study in clinical drug development.Possibly the most significant regulatory shift in cardiac safety since the original E14 Guidance was adopted by the ICH in 2005, the new revision emerged following the successful conduct of a prospective validation study in 2014 that was sponsored by iCardiac and which utilized iCardiac’s personnel and technology to perform the critical data analysis. Read more
- Health Business Blog- ICH endorses a faster, less expensive approach to cardiac safety testing: Drug developers must demonstrate that new medications are safe and effective in order to win regulatory approval. The gold standard in cardiac safety testing has been the Thorough QT study, a separate, expensive trial that is typically conducted late in the clinical development process.The international body that informs drug development standards has just revised its stance to support definitive QT testing based on ECGs collected during existing early-stage trials. iCardiac Technologies, where I’m a board member, pioneered this approach in conjunction with the FDA. I asked iCardiac’s CEO Alex Zapesochny to explain what is happening. Read more
- Rochester Business Journal- iCardiac Acquires Key Firm: ICardiac Technologies Inc. has made its move beyond the heart. The Brighton company, whose technology assesses the cardiac safety of drugs, has acquired the clinical trials division of nSpire Health Inc. in Colorado, adding respiratory services to its lineup. Read more
- OutsourcingPharma.com- iCardiac acquires clinical trials division of nSpire Health: Cardiac safety assessment service provider iCardiac Technologies has added respiratory and ePRO services to its offerings through the acquisition of the clinical trials division of nSpire Health. Read more
- DDN News- Arresting Cardiac Risks ROCHESTER, N.Y.: Pharmaceutical companies may soon have an opportunity to significantly streamline and reduce the cost of developing new drugs. A study recently released by the U.S. Food and Drug Administration (FDA) suggests that a new means of testing drugs for cardiac safety—an FDA requirement—could take place much earlier in the clinical development process than current methods of testing allow. Read more
- Time Warner Cable News- University of Rochester Creates Spinoff Company iCardiac: ROCHESTER, N.Y. — Health and medicine in New York State have led to many medical advancements and as a result, spinoff companies. iCardiac is one of those, created at the University of Rochester. Read more
- Applied Clinical Trials- iCardiac Launches Full Risk-Sharing Program for Cardiac Safety Studies: In a move designed to both tout the importance of precision and to improve the sponsor experience in conducting cardiac safety assessment, iCardiac Technologies announced a full risk-sharing program for Thorough QT studies. Read more
- Rochester Democrat & Chronicle- iCardiac Acquires Unit of nSpire Health: iCardiac Technologies Inc. has announced that it has acquired the clinicial trials division of nSpire Health out of Colorado. The Brighton-based cardiac safety assessment services firm said on Thursday that it has opened an office in Longmont, Colorado, to handle various business-related services as part of the deal. Read more
- Biospace- ICON Partners With iCardiac Technologies to Provide An Earlier and More Precise Method for Evaluating Cardiac Safety: Read more
- Biospace- Vince & Associates Clinical Research Qualified as Early Phase Provider for Clinical Evaluation of Thorough QT: Vince & Associates Clinical Research, a premier provider of early phase clinical research services, announced today it has become the first “iCardiac Certified Site.” iCardiac is a major provider of cardiac safety services. Read more
High Point Clinical Trials Center Announces Initiative Providing Free Medical Screenings to Community
iCardiac Technologies will assist High Point Clinical Trials Center’s volunteer outreach efforts through donation of electrocardiogram and spirometry equipment and support
APRIL 11, 2017—HIGH POINT, N.C.—High Point Clinical Trials Center (HPCTC) announced today a joint initiative with iCardiac Technologies, Inc. to support the patient outreach efforts undertaken by the Medical Team at HPCTC. iCardiac has agreed to provide electrocardiograms and spirometers to the local community clinic where physicians from HPCTC perform volunteer medical services. Read more
iCardiac Unveils QPoint, an Innovative and Highly-Customizable eCOA Platform
QPoint enables the shortest and most efficient study configuration and startup in the industry
FEBRUARY 22, 2017 – ROCHESTER, N.Y. – iCardiac Technologies, Inc. announced today that it has launched QPoint, its next-generation eCOA platform, to address the growing demand for more efficient and innovative eCOA study services in drug development. In addition to a number of other benefits, QPoint delivers the shortest and most streamlined study configuration and startup in the industry. Read more..
iCardiac Launches Training Standardization Tool to Minimize Variability in Spirometry Studies
The direct-to-subject videos facilitate consistent and high quality pulmonary testing across trial sites
January 31, 2017 – ROCHESTER, N.Y. – iCardiac Technologies, Inc., a leading centralized core laboratory specializing in respiratory and cardiac safety studies, announced today it has launched a Direct-to-Subject Pre-Coaching™ video tool to help minimize the variability in respiratory test data caused by differences in subject technique and technician coaching. The training videos will be embedded in equipment iCardiac sends to all trial sites and are brief enough to be shown to subjects at the beginning of each testing visit. Read more…
iCardiac and SNBL Clinical Pharmacology Center, Ltd. (SNBL CPC Japan) Enter Collaboration Agreement
The companies will work together on cardiac safety studies in Japan
September 7, 2016, Rochester, N.Y. and Tokyo, Japan—iCardiac Technologies, Inc., a market and innovation leader in cardiac safety and respiratory studies, and SNBL CPC Japan, an experienced and reputable Site Management Organization (SMO) have announced that they will collaborate on cardiac safety studies in Japan.Read more
iCardiac CEO, Alex Zapesochny, Honored with PharmaVOICE 100 Selection
The list recognizes the most inspiring leaders in the life sciences industry
August 3, 2016, Rochester, N.Y.—iCardiac Technologies, Inc., a market and innovation leader in cardiac safety and respiratory studies, has announced that its CEO, Alex Zapesochny, has been named to the prestigious PharmaVOICE 100 list, which honors the most inspiring individuals in the life sciences industry. Read more
iCardiac Implements New Quality Metric to Enhance Reliability of Phase I QT Assessment
The metric is intended to accelerate the use of Phase I QT data as an alternative to the TQT study
April 20, 2016, Rochester, N.Y.—iCardiac Technologies, Inc., a market and innovation leader in cardiac safety and respiratory studies, announced today that it has implemented a new, advanced quality metric into its Phase I QT assessment services.
Rochester Democrat & Chronicle names iCardiac Technologies a Winner of the 2016 Rochester Metro Area Top Workplaces Award
March 29, 2016, Rochester, N.Y. – iCardiac Technologies, Inc. has been awarded a 2016 Top Workplaces honor by the Rochester Democrat & Chronicle for the second time.
iCardiac Launches Newly Named “PFT Global” Service Line, Completing Post-Merger Integration
The move rebrands the respiratory services acquired by iCardiac and reflects enhanced capabilities March 22, 2016, Rochester, NY – iCardiac Technologies, Inc., a market leader in the conduct of respiratory and cardiac safety studies, today unveiled “PFT Global”, the new name of its respiratory testing service line.
iCardiac Launches Global Late Phase Respiratory and Cardiac Safety Study Spanning 28 Countries
The Phase III trial, the largest in the company’s history, will assess 14,000 subjects across 750 sites February 24, 2016, Rochester, NY – iCardiac Technologies, Inc., a market leader in the conduct of respiratory and cardiac safety studies, today announced it was awarded and is now enrolling patients in the largest late phase respiratory and cardiac safety study in the company’s history.
iCardiac Shares Pivotal Dataset to Enable Industrywide Validation of a TQT Alternative
The validation program is the latest milestone driving the rapid adoption of the new approach
January 11, 2016, Rochester, NY – iCardiac Technologies, Inc., a scientific leader in the conduct of cardiac safety assessments, today announced it is providing industrywide access to its pivotal dataset as part of an effort announced by the Cardiac Safety Research Consortium to enable broader validation of an alternative approach to the Thorough QT (TQT) study.
Landmark Regulatory Revision Ushers in an Alternative to the Thorough QT Study
iCardiac, a key contributor, will conduct public webinars explaining the benefits to sponsors
December 21, 2015, Rochester, N.Y. – iCardiac Technologies, Inc., a scientific leader in the conduct of cardiac safety assessments, today applauded the official release of a regulatory revision enacted by the International Council for Harmonisation (ICH) that defines and enables an alternative path to the conduct of a Thorough QT (TQT) study in clinical drug development. Likely the most significant regulatory shift in cardiac safety since the original E14 Guidance was adopted by the ICH in 2005, the new revision emerged following the successful conduct of a prospective validation study in 2014 that was sponsored by iCardiac and which utilized iCardiac’s personnel and technology to perform the critical data analysis.
iCardiac Acquires Clinical Trials Division Of nSpire Health
Transaction Adds Respiratory and ePRO Services to Its Leading Cardiac Safety Offering
August 6, 2015, Rochester, N.Y.- iCardiac Technologies, a global provider of cardiac safety assessment services to the pharmaceutical industry, announced recently that it has added leading respiratory and ePRO services to its suite of offerings through the acquisition of the clinical trials division of nSpire Health.
Ms. Smriti Jacob
Sr. manager, marketing and communications
Phone: +1-585-295-7610 x 188